Compare Abbott Laboratories (ABT) vs Global X Cybersecurity (BUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Global X Cybersecurity — how do they compare? Abbott Laboratories trades at $109.66 (market cap $187.95B), while Global X Cybersecurity trades at $42.93. The key difference: Abbott Laboratories pays a 2.32% dividend while Global X Cybersecurity pays none, and Global X Cybersecurity is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | BUG | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $43.00 |
52-Week Low | $82.57 | $23.30 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $107.80, down slightly by 0.14% today. The stock shows a bullish technical signal with strong moving average support and a consensus analyst price target of $120.70. Recent earnings beat expectations in Q1 and Q2 2026, while revenue grew to $44.33 billion in 2025. The company secured a CE Mark for its Libre Duo glucose-ketone sensor, highlighting innovation in diabetes care.
The outlook remains positive given analyst consensus and recent product approvals, but risks include competitive pressures and macroeconomic volatility. Upside potential exists if earnings momentum continues, though valuation multiples are above industry averages, warranting caution on significant expansion.
BUG, the Global X Cybersecurity ETF, trades at $41.68, up 2.36% today and near its 52-week high, with a strong bullish technical signal from moving averages. The ETF has gained significant momentum, rising 82.25% from its 52-week low, as cybersecurity spending forecasts exceed $300 billion in 2026. Recent news highlights sector resilience against AI threats, though key financial ratios like P/E and P/S are not provided in the available data.
The outlook for BUG is positive, driven by robust cybersecurity demand and AI-related security needs, but risks include premium valuations, concentrated US SMID-cap exposure, and potential sector volatility. Analyst sentiment remains bullish with reiterated buy ratings, yet investors should note overbought short-term signals and competitive pressures in the evolving tech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →
